文献速递脑血管病

F2R基因多态性与缺血性卒中72小时内启动氯吡格雷疗效的关联

F2R Polymorphisms and Efficacy of Clopidogrel Initiated Within 72 Hours for Ischemic Stroke
RSS 订阅 · Stroke

该研究为INSPIRES试验的二次分析,纳入5791例轻型缺血性卒中或TIA伴颅内/外动脉粥样硬化患者,评估F2R多态性与72小时内启动氯吡格雷联合阿司匹林疗效的关联。结果显示,在F2R IVSn-14 T等位基因携带者中,氯吡格雷联合阿司匹林较单用阿司匹林降低新发卒中风险(7.1% vs 9.2%;HR 0.77,95%CI 0.62–0.95;P=0.02),而AA基因型者无显著获益。

要点

  • F2R IVSn-14 T等位基因携带者可从72小时内氯吡格雷联合阿司匹林治疗中获益。
  • AA基因型患者未见氯吡格雷联合阿司匹林显著降低新发卒中风险。
  • CYP2C19功能缺失等位基因状态未改变F2R多态性对临床结局的影响。

核心结论

  • 在轻型缺血性卒中或TIA发病72小时内启动治疗,氯吡格雷联合阿司匹林可能降低F2R IVSn-14 T等位基因携带者的新发卒中风险。

主要发现

  • F2R IVSn-14 AA纯合子1698例(29.3%),T等位基因携带者(AT/TT)4093例(70.7%)。
  • T等位基因携带者中,氯吡格雷联合阿司匹林组新发卒中7.1%,单用阿司匹林组9.2%(HR 0.77,95%CI 0.62–0.95;P=0.02)。
  • AA基因型者中新发卒中率7.7% vs 8.1%(HR 0.95,95%CI 0.67–1.33;P=0.75;交互P=0.30)。
  • 中重度出血风险在T等位基因携带者(HR 1.91,95%CI 0.85–4.29;P=0.12)和AA基因型者(HR 1.97,95%CI 0.59–6.55;P=0.27;交互P=0.97)均无显著差异。
  • 至少携带1个F2R IVSn-14 T等位基因且无CYP2C19功能缺失等位基因者,氯吡格雷联合阿司匹林较单用阿司匹林卒中风险边缘降低(HR 0.73,95%CI 0.52–1.01;P=0.06)。

临床怎么用

  • 对于轻型缺血性卒中或TIA伴颅内/外动脉粥样硬化患者,若携带F2R IVSn-14 T等位基因,72小时内启动氯吡格雷联合阿司匹林可能获益更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stroke, Ahead of Print. BACKGROUND:The aim of this study was to investigate the association between PAR-1 (protease-activated receptor-1) geneF2Rpolymorphisms and the efficacy of clopidogrel therapy initiated within a time window extended to 72 hours for mild ischemic stroke or transient ischemic attack with intracranial or extracranial atherosclerosis.METHODS:This was a secondary analysis of the INSPIRES trial (Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis), a randomized clinical trial conducted at 222 centers across China between September 2018 and October 2022. Four single-nucleotide polymorphisms (F2R[IVSn-14 A/T, rs168753],CYP2C19*2[681G>A, rs4244285],CYP2C19*3[636G>A, rs4986893], andCYP2C19*17[−806C>T, rs12248560]) were genotyped among 5791 patients treated with clopidogrel plus aspirin (n=2894) or aspirin alone (n=2897). The primary efficacy outcome was new stroke, and the safety outcome was moderate-to-severe bleeding within 90 days. Cox proportional hazards models were used to estimate the interaction between treatment assignment andF2Rpolymorphisms for the primary outcomes.RESULTS:Among 5791 patients, 1698 (29.3%) were AA homozygotes, and 4093 (70.7%) were the T-allele carriers (AT/TT) forF2RIVSn-14 polymorphisms. Compared with aspirin alone, clopidogrel-aspirin reduced the rate of new stroke in patients with AT/TT genotype (7.1% versus 9.2%; hazard ratio [HR], 0.77 [95% CI, 0.62–0.95];P=0.02) but not in carriers of the AA genotype (7.7% versus 8.1%; HR, 0.95 [95% CI, 0.67–1.33];P=0.75;P=0.30 for interaction). For the safety outcome, the risk of moderate-to-severe bleeding between the clopidogrel plus aspirin group and aspirin group was not significant in patients with AT/TT genotype (HR, 1.91 [95% CI, 0.85–4.29];P=0.12) or AA genotype (HR, 1.97 [95% CI, 0.59–6.55];P=0.27;P=0.97 for interaction). Moreover, the presence ofCYP2C19loss-of-function allele carrier status did not alter the effect of theF2Rpolymorphisms on clinical outcomes, although a marginally reduced risk of stroke with clopidogrel-aspirin versus aspirin alone was observed only among carriers of at least 1F2RIVSn-14 T allele withoutCYP2C19loss-of-function allele (HR, 0.73 [95% CI, 0.52–1.01];P=0.06).CONCLUSIONS:With the treatment initiated within a time window extended to 72 hours after mild ischemic stroke or transient ischemic attack onset, we found that clopidogrel plus aspirin may reduce the occurrence of new stroke sp

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Stroke:F2R Polymorphisms and Efficacy of Clopidogrel Initiated Within 72 Hours for Ischemic Stroke

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。